![]() |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Hanmi Science, led by Vice President Im Jong-hoon, is pushing to remove Hanmi Pharm CEO Park Jae-hyun and Chairman Shin Dong-guk from the board amidst a conflict with a "three-party alliance" consisting of Shin Dong-guk, along with his daughters Song Young-sook and Lim Joo-hyun.
On the 30th, Hanmi Science sent a formal request to Hanmi Pharm, demanding the convening of an extraordinary general meeting to discuss the dismissal of Park and Shin. The company criticized Shin, stating he is a "major shareholder lacking expertise and experience in R&D," highlighting concerns that he criticized Park for spending "too much" on Hanmi Pharm’s core competency—R&D. This criticism points to discussions that undermine both the interests of the company’s members and shareholders regarding major management decisions that secure the company's future value.
Hanmi Science has proposed current Hanmi Science Vice President Park Jun-seok and Hanmi Precision Chemical CEO Jang Young-gil as new board candidates, as they have previously collaborated closely with Im Jong-hoon during his tenure as CEO of Hanmi Healthcare and Hanmi Precision Chemical.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)